Cancer drugs

A practical approach to drugs available to us

What do doxorubicin and adriamycin have in common ? Why can the

indications for platinum compounds vary so much ? Have monoclonal

antibodies ousted cytotoxic drugs ? What is an anticancer antibiotic ?

The aim of this book is to answer these questions, and all those that

arise from being in contact with cancer drugs. To do this, we first need

to classify each one in relation to the others. Each product is then

described, detailing its official indications, as validated by its

marketing license, then its dose, its mode of administration and the

precautions that need to be taken when using it, any eventual

resistance it may generate, and finally, the side effects it may cause.

Although cancer treatments evolve more or less on a daily basis, this

book hopes to enable the public, specialised or not, to navigate more

easily through the maze of the various drug classes.